Big pharma’s key catalysts in the second quarter

The second quarter is gearing up to be important for Biogen: its Alzheimer's asset aducanumab is due a US approval decision, and clinical data from two projects will show whether the company was right to hand over $1.5bn to Sage at the end of last year.

Meanwhile, data with Sanofi’s oral selective oestrogen receptor degrader will need to be good enough for a filing if the company is to get a jump on the competition.